Erik van Duijn1, David Craufurd2, Anna A M Hubers3, Erik J Giltay3, Raphael Bonelli4, Hugh Rickards5, Karen E Anderson6, Marleen R van Walsem7, Rose C van der Mast3, Michael Orth8, G Bernhard Landwehrmeyer8. 1. Department of Psychiatry, Leiden University Medical Centre, Leiden, The Netherlands Centre for Mental Health Care Delfland, Delft, The Netherlands. 2. Insitute of Human Development, University of Manchester, Manchester, UK Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust and Manchester Academic Health Sciences Centre, Manchester, UK. 3. Department of Psychiatry, Leiden University Medical Centre, Leiden, The Netherlands. 4. Sigmund Freud University, Vienna, Austria. 5. Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Birmingham, UK. 6. Department of Psychiatry, Georgetown University, Washington, DC, USA. 7. Research Centre of Habilitation and Rehabilitation Models and Services, Faculty of Medicine, Institute of Health and Society, University of Oslo, Oslo, Norway Division of Surgery and Clinical Neurosciences, Department of Neurohabilitation, Oslo University Hospital, Oslo, Norway. 8. Department of Neurology, University of Ulm, Ulm, Germany.
Abstract
BACKGROUND: The majority of Huntington's disease (HD) mutation carriers experience some psychopathology during their lifetime, varying from irritability to psychosis, but prevalences of particular symptoms vary widely due to diverse study populations in different stages of HD and the use of different assessment methods. METHODS: The study population consisted of 1993 HD mutation carriers from 15 European countries, all participating in the observational REGISTRY study. The behavioural section of the Unified HD Rating Scale was used to examine the prevalence and correlates of five neuropsychiatric features: depression, irritability/aggression, obsessive/compulsive behaviours, apathy and psychosis. RESULTS: Twenty-seven per cent of the participants did not have any neuropsychiatric symptom in the last month. Moderate to severe apathy occurred in 28.1% of the participants, whereas moderate to severe depression was found in 12.7%. Irritable/aggressive symptoms were present in 13.9% of the participants, and 13.2% showed obsessive/compulsive behaviours. Moderate to severe psychotic symptoms were found in only 1.2%. Only 54.9% of all participants with moderate to severe depression used antidepressants, suggesting undertreatment of depression. Obsessive/compulsive behaviours and irritability/aggression were inversely correlated with the Total Functional Capacity score, but with apathy showing the strongest inverse association. CONCLUSIONS: A variety of neuropsychiatric symptoms are highly prevalent in different stages of HD in this European HD population, with apathy as the most frequent symptom. Depression, irritability/aggression and OCBs are prevalent in all stages of HD. Apathy was the key neuropsychiatric symptom occurring most often in advanced HD stages. Due to possible selection of relatively healthy participants, prevalences reported in this study might be an underestimation of prevalence in the entire HD population. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND: The majority of Huntington's disease (HD) mutation carriers experience some psychopathology during their lifetime, varying from irritability to psychosis, but prevalences of particular symptoms vary widely due to diverse study populations in different stages of HD and the use of different assessment methods. METHODS: The study population consisted of 1993 HD mutation carriers from 15 European countries, all participating in the observational REGISTRY study. The behavioural section of the Unified HD Rating Scale was used to examine the prevalence and correlates of five neuropsychiatric features: depression, irritability/aggression, obsessive/compulsive behaviours, apathy and psychosis. RESULTS: Twenty-seven per cent of the participants did not have any neuropsychiatric symptom in the last month. Moderate to severe apathy occurred in 28.1% of the participants, whereas moderate to severe depression was found in 12.7%. Irritable/aggressive symptoms were present in 13.9% of the participants, and 13.2% showed obsessive/compulsive behaviours. Moderate to severe psychotic symptoms were found in only 1.2%. Only 54.9% of all participants with moderate to severe depression used antidepressants, suggesting undertreatment of depression. Obsessive/compulsive behaviours and irritability/aggression were inversely correlated with the Total Functional Capacity score, but with apathy showing the strongest inverse association. CONCLUSIONS: A variety of neuropsychiatric symptoms are highly prevalent in different stages of HD in this European HD population, with apathy as the most frequent symptom. Depression, irritability/aggression and OCBs are prevalent in all stages of HD. Apathy was the key neuropsychiatric symptom occurring most often in advanced HD stages. Due to possible selection of relatively healthy participants, prevalences reported in this study might be an underestimation of prevalence in the entire HD population. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
BEHAVIOURAL DISORDER; DEPRESSION; HUNTINGTON'S; MOVEMENT DISORDERS; NEUROPSYCHIATRY
Authors: Noelle E Carlozzi; Siera Goodnight; Anna L Kratz; Julie C Stout; Michael K McCormack; Jane S Paulsen; Nicholas R Boileau; David Cella; Rebecca E Ready Journal: J Huntingtons Dis Date: 2019
Authors: A González-Baeza; J R Arribas; I Pérez-Valero; S Monge; C Bayón; P Martín; S Rubio; F Carvajal Journal: J Neurovirol Date: 2016-12-09 Impact factor: 2.643
Authors: Edward D Huey; Stephanie Cosentino; Silvia Chapman; Martina Azar; Brittany Rohl; Kathleen Collins; Sarah Morgan; Xinhua Liu; Elan D Louis Journal: Parkinsonism Relat Disord Date: 2018-02-20 Impact factor: 4.891
Authors: Natalie E Zlebnik; Iness Gildish; Thibaut Sesia; Aurelie Fitoussi; Ellen A Cole; Brian P Carson; Roger Cachope; Joseph F Cheer Journal: Cereb Cortex Date: 2019-12-17 Impact factor: 5.357